ZURICH, July 18 (Reuters) - Novartis NOVN.S lifted full-year sales and profit targets on Thursday, helped by innovative medicine sales and as the Swiss drugmaker's slimmed-down Sandoz generics unit saw accelerating revenue in markets outside the United States.
Core operating income rose 20% in constant currencies to $3.6 billion, while sales were up 8% to $11.8 billion, compared to the $11.54 billion forecast by 10 analysts in a Refinitiv poll.
The Basel-based company now expects 2019 core operating income to grow at low-double-digit to mid-teens percentages, faster than the previous high-single-digit percentage rate target. Sales expectations were also raised, with growth now seen in the mid to high-single digit range.
(Reporting by John Miller Editing by Thomas Seythal)
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.